Related Experiment Video
Updated: Oct 15, 2025
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
A novel bioavailable curcumin-galactomannan complex modulates the genes responsible for the development of chronic
Kishore Banik1, Elina Khatoon1, Mangala Hegde1
1Cancer Biology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology-Guwahati, Guwahati 781 039, Assam, India; DBT-AIST International Center for Translational and Environmental Research, Indian Institute of Technology-Guwahati, Guwahati 781 039, Assam, India.
Background:
Chronic diseases or non-communicable diseases are a major burden worldwide due to the lack of highly efficacious treatment modalities and the serious side effects associated with the available therapies.
Purpose/Study Design:
A novel self-emulsifying formulation of curcumin with fenugreek galactomannan hydrogel scaffold as a water-dispersible non-covalent curcumin-galactomannan molecular complex (curcumagalactomannosides, CGM) has shown better bioavailability than curcumin and can be used for the prevention and treatment of chronic diseases. However, the exact potential of this formulation has not been studied, which would pave the way for its use for the prevention and treatment of multiple chronic diseases.
Methods:
The whole transcriptome analysis (RNAseq) was used to identify differentially expressed genes (DEGs) in the liver tissues of mice treated with LPS to investigate the potential of CGM on the prevention and treatment of chronic diseases. Expression analysis using DESeq2 package, GO, and pathway analysis of the differentially expressed transcripts was performed using UniProtKB and KEGG-KAAS server.
Results:
The results showed that 559 genes differentially expressed between the liver tissue of control mice and CGM treated mice (100 mg/kg b.wt. for 14 days), with adjusted p-value below 0.05, of which 318 genes were significantly upregulated and 241 were downregulated. Further analysis showed that 33 genes which were upregulated (log2FC > 8) in the disease conditions were significantly downregulated, and 32 genes which were downregulated (log2FC < -8) in the disease conditions were significantly upregulated after the treatment with CGM.
Conclusion:
Overall, our study showed CGM has high potential in the prevention and treatment of multiple chronic diseases.
Insights
Curcumin-galactomannan molecular complex (CGM) shows significant potential for treating chronic diseases by modulating gene expression in liver tissues. This novel formulation offers a promising therapeutic strategy with improved bioavailability.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology and Toxicology
- Genomics and Transcriptomics
Background:
- Chronic diseases represent a significant global health burden.
- Current treatments for chronic diseases often lack efficacy and cause adverse side effects.
- There is a critical need for novel therapeutic strategies to manage chronic diseases effectively.
Purpose of the Study:
- To investigate the therapeutic potential of a novel curcumin-galactomannan molecular complex (CGM) for chronic diseases.
- To evaluate the bioavailability and efficacy of CGM compared to curcumin alone.
- To explore the underlying molecular mechanisms of CGM action using transcriptome analysis.
Main Methods:
- Whole transcriptome analysis (RNAseq) was employed to identify differentially expressed genes (DEGs) in mouse liver tissues.
- Mice were treated with lipopolysaccharide (LPS) to induce a disease model and subsequently with CGM.
- Gene expression analysis was performed using DESeq2, Gene Ontology (GO), and KEGG Pathway analysis.
Main Results:
- Treatment with CGM resulted in significant differential expression of 559 genes in mouse liver tissue (adjusted p-value < 0.05).
- CGM treatment led to the upregulation of 318 genes and downregulation of 241 genes.
- Notably, CGM reversed the expression of key genes associated with disease conditions, with 33 upregulated genes significantly downregulated and 32 downregulated genes significantly upregulated.
Conclusions:
- The novel curcumin-galactomannan molecular complex (CGM) demonstrates significant potential for the prevention and treatment of multiple chronic diseases.
- CGM exhibits therapeutic effects by modulating gene expression patterns in the liver.
- Further research into CGM is warranted to fully elucidate its therapeutic applications for chronic disease management.
